CytomX Therapeutics (CTMX) Gains from Sales and Divestitures (2022 - 2025)
Historic Gains from Sales and Divestitures for CytomX Therapeutics (CTMX) over the last 4 years, with Q3 2025 value amounting to $527238.0.
- CytomX Therapeutics' Gains from Sales and Divestitures fell 2541.79% to $527238.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $527238.0, marking a year-over-year decrease of 2541.79%. This contributed to the annual value of $733201.0 for FY2024, which is 6689.11% up from last year.
- Per CytomX Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $527238.0 for Q3 2025, which was down 2541.79% from $527238.0 recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Gains from Sales and Divestitures peaked at $733201.0 during Q4 2024, and registered a low of $110892.0 during Q1 2023.
- Over the past 4 years, CytomX Therapeutics' median Gains from Sales and Divestitures value was $521404.0 (recorded in 2025), while the average stood at $462613.8.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 53748.78% in 2024, then crashed by 2624.32% in 2025.
- Quarter analysis of 4 years shows CytomX Therapeutics' Gains from Sales and Divestitures stood at $193750.0 in 2022, then surged by 126.75% to $439329.0 in 2023, then surged by 66.89% to $733201.0 in 2024, then decreased by 28.09% to $527238.0 in 2025.
- Its Gains from Sales and Divestitures was $527238.0 in Q3 2025, compared to $527238.0 in Q2 2025 and $521404.0 in Q1 2025.